ADIAL PHARMACEUTICALS, INC. short interest in 2023
In 2023, ADIAL PHARMACEUTICALS, INC.'s disclosed short interest ran from 0.54% of shares outstanding on 13 Jan 2023 to 2.74% on 29 Dec 2023, a change of +2.20 percentage points. The year's high was 5.30% on 31 Aug 2023 and its low 0.50% on 31 Jan 2023, averaging 2.33% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.55 days on 15 Nov 2023. Full history: ADIAL PHARMACEUTICALS, INC..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 0.54% (13 Jan 2023)
- End of year
- 2.74% (29 Dec 2023)
- Change
- +2.20 pp
- High
- 5.30% (31 Aug 2023)
- Low
- 0.50% (31 Jan 2023)
- Average
- 2.33%
- Highest days to cover
- 4.55 (15 Nov 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.54% | 1.00 | |
| 31 Jan 2023 | 0.50% | 1.00 | |
| 15 Feb 2023 | 1.03% | 1.00 | |
| 28 Feb 2023 | 1.42% | 1.83 | |
| 15 Mar 2023 | 2.02% | 1.00 | |
| 31 Mar 2023 | 1.16% | 2.37 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 1.02% | 1.34 | |
| 28 Apr 2023 | 1.46% | 1.00 | |
| 15 May 2023 | 1.14% | 2.65 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 5.30% | 1.02 | 10-Q filed, results (8-K) |
| 15 Sep 2023 | 2.79% | 1.00 | |
| 29 Sep 2023 | 4.17% | 1.00 | |
| 13 Oct 2023 | 2.29% | 2.46 | |
| 31 Oct 2023 | 4.42% | 1.56 | |
| 15 Nov 2023 | 4.35% | 4.55 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 3.38% | 1.00 | |
| 15 Dec 2023 | 2.12% | 1.00 | |
| 29 Dec 2023 | 2.74% | 1.00 |
See also: ADIAL PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.